Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven carcinoma of the pancreas that is locally advanced~* ECOG performance status 0- 2~* Adequate labs~* No prior abdominal radiation therapy~* No other concurrent clinically evident malignancy, except inactive nonmelanoma skin cancer, inactive cervical cancer, or other cancer for which the patient has been disease-free for 5 years~* All disease must be encompassed within a radiotherapy portal~* Not pregnant or nursing~Exclusion Criteria:~* Patient has metastatic disease on radiological staging~* systemic therapy.~* Patient has known active infection with HIV, hepatitis C or hepatitis B~* Patient has serious medical risk factors involving any of the major organ systems such that the Investigator considers it unsafe for the patient to receive an experimental research drug.~* Patient is deemed to be have obvious resectable disease at presentation~* Received any investigational agent within a month prior to enrollment.~* Neuroendocrine tumors of the pancreas

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemzar/Abraxane and Radiation Therapy (Type: EXPERIMENTAL): Patients will receive 2 cycles of gemcitabine and abraxane prior to the start of chemoradiation. Chemoradiation will commence 2 week after the completion of second cycle of gemcitabine/abraxane. Patients will receive an additional 2 cycles of gemcitabine and abraxane to start 2-4 weeks after the completion of chemoradiation. After the last two cycles of chemotherapy, if well tolerated with continued tumor response additional cycles of chemotherapy may be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).